← Back to All Filings

Pediatrix Director Files Intent to Sell $216K in Company Stock

Low SignificanceNovember 6, 2025 at 4:31:57 PM EST

Pediatrix Medical Group, Inc.

$MD144CIK: 0000893949

Subscribe to track MD

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Pediatrix Director Files Intent to Sell $216K in Stock

Company: Pediatrix Medical Group, Inc. (MD) Form: 144 | Filed: 2025-11-06 Significance: Low

Insider: Laura A Linynsky Title: Director | Relationship: Director

Transaction: • Type: Proposed Sale • Shares: 10,000 • Price: ~$21.62 • Value: $216,150 • Owned After: Not Disclosed

Key Insight: A director has filed a notice of a proposed sale of 10,000 shares. The transaction size is minor, representing just 0.012% of the company's market cap.

Market Context: This Form 144 filing signals an intent to sell and is considered a routine disclosure for insiders. Given its small size, it is unlikely to have a material impact on the stock.

Comprehensive Analysis

SEC Filing Analysis: Pediatrix Medical Group, Inc. (MD)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A director at Pediatrix Medical Group has filed a notice of proposed sale for 10,000 shares, a transaction with minimal financial scale relative to the company's size.
  • Market Impact: Negligible market impact is expected due to the transaction's small value and share volume.

Company Information

FieldValue
CompanyPediatrix Medical Group, Inc.
Ticker SymbolMD
CIK0000893949
IndustryServices-Hospitals

Insider Information

FieldValue
NameLaura A Linynsky
CIK0001543891
Title/PositionDirector
RelationshipDirector

Transaction Details

FieldValue
Form Type144
Transaction Date2025-11-06 (Approximate Sale Date)
Transaction CodeS (Proposed Sale)
Security TypeCommon Stock
Shares Involved10,000
Price Per Share$21.615 (implied)
Total Value$216,150
Shares Owned AfterNot Disclosed
Ownership TypeNot Disclosed

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$216,150
% of Market Cap0.012%
Shares Transacted10,000
% of Shares Outstanding0.011%
Post-Transaction OwnershipNot Disclosed
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The $216,150 proposed sale is insignificant compared to Pediatrix's $1.86 billion market capitalization.
  • Ownership Concentration: Without post-transaction ownership data, it's impossible to assess the sale's impact on the insider's holdings, but the number of shares sold is a very small fraction of the total shares outstanding.
  • Transaction Significance: The sale represents just 0.012% of the market cap and 0.011% of shares outstanding, placing it well below any threshold for material significance. This is considered a routine, non-impactful transaction.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is too small to signal any meaningful information or to affect supply/demand dynamics for the stock. It is a routine filing of intent to sell.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The 10,000 shares can likely be absorbed by the market with no noticeable impact on trading volume.
  • Sentiment Indicator: Neutral. A small sale by a director is common for personal financial management and does not typically carry a strong market signal.

Additional Context

Transaction Notes

  • This Form 144 is a notice of proposed sale, meaning the sale is intended to happen on or around the approximate sale date but has not yet been executed. The shares to be sold were originally acquired through stock plan activity.
Topics:#SECFiling#InsiderTrading#Form144#InsiderSell#Pediatrix#MD#StockMarket#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.